Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protein Sciences To Begin Selling Novel Flu Vaccine; Flublok Has Virus-Free Appeal

This article was originally published in The Pink Sheet Daily

Executive Summary

The trivalent vaccine can be produced much faster than traditional vaccines and could be modified to compete with quadrivalent formulations.

You may also be interested in...



CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014

Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.

CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014

Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.

Flu Vaccines Likely To Remain Immune From Comparative Effectiveness

CDC’s Advisory Committee on Immunization Practices adds four recently-approved flu vaccines to its recommended list of products, but the committee chair expresses doubt that there could ever be data to make preferential recommendations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel